Copyright
©The Author(s) 2017.
World J Cardiol. Jun 26, 2017; 9(6): 470-480
Published online Jun 26, 2017. doi: 10.4330/wjc.v9.i6.470
Published online Jun 26, 2017. doi: 10.4330/wjc.v9.i6.470
Table 1 Differences in between physiological and pathological hypertrophy
Physiological hypertrophy | Pathological hypertrophy |
Angiogenesis, release of VEGF | Perivascular fibrosis and inflammation |
Activation of IGF-1 pathway (IGF-1- > PI3K- > Akt) | Activation of Angiotensin II, Catecholamine and Endotelin-1 |
No fibrosis | MAPK and Calcineurin pathway |
Normal gene expression | Fibrosis, myocyte necrosis and apoptosis |
Proportional chamber enlargement | Cardiac dysfunction |
- Citation: Carbone A, D’Andrea A, Riegler L, Scarafile R, Pezzullo E, Martone F, America R, Liccardo B, Galderisi M, Bossone E, Calabrò R. Cardiac damage in athlete’s heart: When the “supernormal” heart fails! World J Cardiol 2017; 9(6): 470-480
- URL: https://www.wjgnet.com/1949-8462/full/v9/i6/470.htm
- DOI: https://dx.doi.org/10.4330/wjc.v9.i6.470